The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016
X Chen, M Schaufelberger, M Fu - Journal of Cardiovascular …, 2020 - journals.lww.com
Background The PARADIGM-HF trial showed that sacubitril–valsartan–an angiotensin
receptor-neprilysin inhibitor (ARNI)–is more effective than enalapril for some patients with
heart failure. However, the eligibility of the PARADIGM-HF study to a real-world heart failure
population was not well established. Methods We made secondary analysis of patients (n=
4872) with heart failure prospectively enrolled in the Swedish Heart Failure Registry from
Sahlgrenska University Hospital/Östra Hospital, Sweden during 2005–2016. The eligibility of …
receptor-neprilysin inhibitor (ARNI)–is more effective than enalapril for some patients with
heart failure. However, the eligibility of the PARADIGM-HF study to a real-world heart failure
population was not well established. Methods We made secondary analysis of patients (n=
4872) with heart failure prospectively enrolled in the Swedish Heart Failure Registry from
Sahlgrenska University Hospital/Östra Hospital, Sweden during 2005–2016. The eligibility of …
以上显示的是最相近的搜索结果。 查看全部搜索结果